Background and objectives Peritoneal dialysis is still used for AKI in developing countries despite concerns about its limitations. The objective of this study was to explore the role of high-volume peritoneal dialysis in AKI patients in relation to metabolic and fluid control, outcome, and risk factors associated with death.
Introduction
Peritoneal dialysis (PD) was the first modality of renal replacement therapy used for AKI patients (1) . In the 1970s, acute PD was widely accepted for AKI treatment, but its practice declined in favor of hemodialysis (2-5). It is frequently used in developing countries because of its lower cost and minimal infrastructural requirements (4, 5) . Recently, interest in using PD to manage AKI patients has been increasing. One important question is whether PD can provide adequate metabolic and fluid control for treating AKI patients.
The work by Gabriel et al. (6) showed that, with careful thought and planning, critically ill patients can be successfully treated by PD. To overcome some of the classic limitations of PD use in AKI, such as a high chance of infection and no metabolic control, they proposed the use of cycles, flexible catheter, and a high volume of dialysis fluid.
However, it is also true that PD is not the most efficient therapy: clearance per exchange can decrease if a shorter dwell time is applied, a lower efficiency can be observed in large-sized and severely hypercatabolic patients, fluid removal can be limited, and there is a high risk of infection and possibility of PD worsening mechanical ventilation, thus impairing respiratory performance (7) (8) (9) (10) (11) .
Given the paucity of good-quality evidence in this important area, additional studies on the use, dose, and limitations of PD for AKI and its effect on clinical outcomes are necessary. The goals of this study were to explore the role of high-volume (HV) PD in AKI patients in relation to metabolic and fluid control and identify the risk factors associated with death.
Materials and Methods

Study Population
This study was a prospective cohort study approved by the ethics committee of the Botucatu School of Medicine University Hospital, Sao Paulo, Brazil; 205 patients who had been consecutively treated by HVPD were evaluated between January of 2004 and January of 2011. Informed consent was obtained from study participants or their legal caregiver.
The inclusion criteria were AKI patients according to Acute Kidney Injury Network criteria (12) , clinical diagnosis of septic AKI, and severe acute tubular necrosis (ATN) caused by ischemic or nephrotoxic injury. Indications for dialysis were uremia or azotemia (BUN.100 mg/dl), fluid overload (after diuretics use), electrolyte imbalance (K.6.5 mEq/L after clinical treatment), and acid-base disturbances (pH,7.1 and bicarbonate,10 mEq/L after clinical treatment).
Exclusion criteria were age under 18 years, severe CKD (baseline serum creatinine.4 mg/dl), renal transplantation, pregnancy, severe hypercatabolism according to the criteria of Schrier (13) , absolute contraindication for PD such as recent abdominal surgery (,1 month), multiple abdominal surgeries (more than three), severe hyperkalemia with electrocardiogram changes, severe respiratory failure (FiO 2 .70%), severe fluid overload, and patients submitted to less than one session of HVPD (6, 9, 11) . If patients presented any one of these contraindications, they were treated by intermittent conventional, prolonged, or continuous hemodialysis (HD) according to their hemodynamic instability.
Study Protocol
An HVPD session was defined as 24 h with sessions performed 7 d/wk. Peritoneal access was established by the blind percutaneous placement of a flexible catheter using a Trocath-introduced paramedian. Cephazolin was used as a prophylactic antibiotic to cover the PD catheter insertion. Patients were treated with continuous HVPD, and exchanges with Dianeal PD solution (Na=135 mEq/L, Ca=3.5 mEq/L, K=0 mEql/L, Mg=1.5 mEq/L, lactate=40 mEq/L, 1.5%-4.25% glucose) were performed using HOMECHOICE cycler. The prescribed HVPD dose was determined by Kt/V (14) , where K is the volume of dialysis solution prescribed in 24 h (in milliliters)30.6 (considering the relationship of urea nitrogen (UN) dialysate/ plasma=0.6 in 1 hour), t is treatment duration (1 day), and V is the volume (in liters) of body urea distribution by the formula by Watson et al. (15) . The prescribed Kt/V value was 0.6/session; 2-L exchanges were performed with 30-60 minutes of dwell time (total of 36-44 L/d and 18-22 exchanges/d). To evaluate the adequacy of the dialysis, daily delivered Kt/V, ultrafiltration (UF), and patients' catabolic rates were calculated.
The delivered HVPD dose was determined by urea Kt/V, where K was the mean dialysate UN in milligrams per 100 milliliters/plasma UN pre-and postdialysis in milligrams per 100 milliliters3drained volume in 24 h in milliliters/ volume of body urea distribution in milliliters (14, 16) . Blood samples were collected at the beginning and end of each HVPD dialysis session and analyzed for creatinine, potassium, bicarbonate, glucose, and sodium levels. One aliquot of 3 ml of all the spent dialysate was collected in every session to measure UN. Dialysate white blood cell count and cultures were also determined every 3 days.
Patients' catabolic rate was calculated based on nitrogen balance (NB), and patients were classified according to their NB as being mildly hypercatabolic (NB,26 g/d), moderately hypercatabolic (NB between 26 and 212 g/d), and severely hypercatabolic patients (NB.212 g/d) (17) .
Dietary protein was calculated from a 24-h dietary intake of patients closely supervised by a renal dietician. Two patients were excluded from the NB calculation, because they received an oral diet, leading to an unreliable measurement of protein intake.
Anthropometric measurements (weight, height, and body surface area) were obtained before dialysis. Body surface area was calculated from the Du Bois formula (18) . Mobile patients were weighed on a digital scale, and the weight of immobilized patients was obtained by a bed scale or calculated from two variables formula (19) .
Other variables, including the etiology of AKI, urine output, number of dialysis sessions, need for mechanical ventilation, presence of hemodynamic instability, and patient outcome, were analyzed. Thereafter, patients treated with HVPD were divided into two groups (survival and no survival) and then compared. Patients who had changed the dialysis method were excluded from this analysis.
The protocol was interrupted when there was partial recovery in renal function (urine output.1000 ml/d) and progressive drop in creatinine (,4 mg/dl) and BUN levels (,50 mg/dl), need to change dialysis method because of infectious and mechanical complications, or inefficacy of HVPD in failing to remove fluid and solute for more than 30 days of follow-up or death.
Statistical Analyses
Results are presented as mean and SD or median according to normality characteristics for each variable with a 5% significance level; t test was used to compare parametric variables between two groups and ANOVA followed by the Newman-Keuls test for multiple comparisons between groups. For nonparametric variables, Wilcoxon and KruskalWallis tests followed by Dunn's method were used to compare two groups and multiple groups, respectively. For analysis of repeated measures, the Proc mixed program was used.
Categorical variables were expressed as proportions and compared with the chi-squared test. Variables with significant univariate associations were candidates for multivariable analysis. Longitudinal multivariable logistic regression was performed using backward variable selection, with the exit criteria set at P,0.25. Variables not selected by the automated procedure were added back into the models individually to evaluate residual confounding, and covariate and propensity score adjustments were used to adjust for baseline differences. Statistical analyses were conducted using SAS version 9.2 for Windows (May of 2010).
Results
During the study period (7 years), a total of 722 patients were treated by dialysis: 204 by HVPD (28.2%) and 518 by HD (71.8%), of which 194 were treated by conventional, 241 were treated by prolonged, and 83 were treated by continuous HD.
Fifty-four patients treated with HVPD were withdrawn (26.5%); 20 patients had mechanical complications related to the peritoneal catheter in the first 24 h of dialysis, and 34 patients died during the first dialysis session. Causes of death were not associated with PD catheter insertion or therapy. The main cause of death was refractory septic shock (82.6%); 150 patients (80.2%) were included in the final analysis.
The mean age was 63.8615.8 years, 71.3% of patients were male, 84% of patients were Caucasian, and the mean patient weight was 66.6610.7 kg (47.3% were obtained by a digital scale, 40.2% were obtained by bed scale, and 12.5% were calculated from two variable formulas). Most of the patients (70%) were in the intensive care unit and needed vasoactive drugs and mechanical ventilation (68.7% and 78.6%, respectively); 69.3% of patients had oliguria, and the mean ATN-index specific score (ISS) was 0.6460.18. Sepsis was the main cause of AKI (54.7%) followed by heart failure (24.7%). Uremia or azotemia was the main indication for dialysis (60%). The median number of HVPD sessions was 7, with a range of 5-11. Table 1 shows the metabolic control and fluid balance after HVPD initiation. BUN and creatinine levels stabilized after four sessions, and bicarbonate and pH levels stabilized after three sessions. The mean UF increased steadily from one to three sessions and stabilized after four sessions at around 1.200 ml/d. There was a progressive increase in NB values from two to five HVPD sessions, with NB stabilization after five sessions. Table 2 shows the prescribed and delivered dialysis dose parameters. The delivered urea Kt/V was 0.5160.1/session and 3.560.68/wk.
Peritonitis occurred in 18 patients (12%) after 5.161.6 HVPD sessions. Eleven patients (61.1%) had the catheter removed, and the dialysis method was changed because of no improvement in laboratory or clinical parameters after 5 days of correct antibiotic treatment. The main etiologic agents were Pseudomonas aeruginosa or fungi. Antibiotic treatment was maintained from 14 to 21 days.
Only 11 patients presented mechanical complications (7.3%), and leakage and tip catheter migration were the majority of the complications (75%), with therapy being interrupted in 36% of the patients. In other cases, the catheter was reinserted, and the dialysate volume per cycle was reduced (1500 ml/cycle).
Concerning patient outcome, 22.7% of patients recovered renal function, whereas 6.6% were kept on dialysis after 30 days of therapy. Change of the dialysis method occurred in 13.3% of patients because of refractory peritonitis or mechanical complications (leakage or UF failure). The mortality rate was 57.3% in patients treated with HVPD. Figure 1 shows patient outcome. Afterward, patients were divided into survival (S) and no survival (NS) groups. Those patients who had changed their dialysis method were excluded from this analysis.
The groups were similar in sex, and azotemia was the main indication of dialysis. There was no difference between the S and NS patients in metabolic control. The groups had similar values of delivered Kt/V per session and per week (NS: 0.5260.15 versus S: 0.4960.14, P=0.62; NS: 3.660.8 versus S: 3.460.7, P=0.57) and rate of infectious and mechanical complications (NS: 13% versus S: 11%, P=0.57; NS: 8.2% versus S: 6.9%, P=0.79, respectively). Tables 3 and 4 show the metabolic control and parameters of dialysis adequacy.
There was significant difference between the groups in age (NS: 56.4615.7 versus S: 49.6617.6, P,0.001), ATN-ISS (NS: 0.6860.16 versus S: 0.5760.13, P,0.001), main diagnosis (sepsis: NS=58.1% versus S=38.6%, P=0.002; cardiovascular disease: NS=20.9% versus S=39.1%, P=0.01), etiology of AKI (septic AKI: NS=81.3% versus S=34.1%, P=0.001; ischemia: NS=26% versus S=50%, P=0.02), vasoactive drug use (NS: 81.3% versus S: 34.1%, P=0.001), time of follow-up, and number of dialysis sessions (NS: 7.162.6 versus S: 12.865.4 days, P=0.001; NS: 5.862.4 versus S: 9.663.6 days, P=0.01, respectively). The two groups also differed in UF and NB values after the second session (Tables 3 and 4) . UF was significantly higher and NB was significantly less negative in the S patients than in the NS group. Table 5 .
Discussion
This prospective study evaluated the effectiveness of HVPD in AKI patients in relation to metabolic and fluid control and identified the risk factors associated with death.
Encouraging results were observed for BUN, creatinine, bicarbonate, and pH levels. There was significant reduction in BUN and creatinine levels, with stabilization of BUN values (,50 mg/dl) and creatinine (,4 mg/dl) after four sessions.
There are few studies on PD in AKI patients, and most studies present conflicting results (6) (7) (8) (9) (10) (11) (20) (21) (22) (23) (24) (25) (26) (27) (28) . The work by Chitalia et al. (22) elegantly showed that tidal PD and continuous PD should be adequate methods to keep BUN levels around 65 mg/dl in mildly and moderately (24) reported that intermittent PD was not adequate to maintain BUN levels higher than 75 mg/dl. The work by Phu et al. (25) showed that PD failed to satisfactorily control BUN and creatinine levels compared with continuous venovenous hemofiltration, with creatinine having a significantly lower mortality rate; however, Phu et al. (25) are comparing procedures performed at different technological levels to the detriment of PD, such as the use of rigid catheters, manual exchanges, and a dwell time that is too short (15 minutes).
There are several methods to measure catabolism, and NB seems to be the most adequate (13, 17, 26) . This study showed that there was an increase in NB values after the third HVPD session, with stabilized values around 21 g/d after five HVPD sessions.
For bicarbonate and pH control, two studies were not in agreement with our data. In this study, acidic-basic balance normalized after two sessions. The works by Phu et al. (25) and Bazari (27) reported that intermittent PD failed to control academia, because PD impairs diaphragm mobilization, with a resulting increase in intra-abdominal pressure and reduction in pulmonary compliance and ventilation. It also causes tissue and organ hypoperfusion and maintains acidosis (29) .
Results of our prospective descriptive study have suggested that AKI patients on invasive mechanical ventilation treated with PD show improvement in mechanical ventilation and oxygenation without changes in intra-abdominal pressure (30) . It evaluated static compliance, respiratory system resistance, and PaO 2 /FiO 2 ratio in patients undergoing PD. The static compliance increased progressively after exchanges of dialysate, respiratory system resistance and intra-abdominal pressure were stable during HVPD sessions, and PaO 2 /FiO 2 increased progressively (30) .
PD dose adequacy in AKI is a subject of controversy. Our results are similar to the results of previous studies that showed that PD clearance was limited by dialysate flow, membrane permeability, and area (6) (7) (8) (9) (10) (11) (20) (21) (22) (23) (24) (25) (31) (32) (33) (34) (35) . A 2-L exchange with a dwell time of 30 minutes can achieve dialysate saturation of around 50%. Therefore, over 24 hours, application of a 2 L/h regimen can be expected to achieve an average clearance of urea of approximately 24 L. That calculation could lead to a Kt/V of 0.6 in a patient with body weight of 70 kg. Recently, some studies have shown that a weekly Kt/V = 3 is enough to keep adequate metabolic control of not severely hypercatabolic AKI patients without any difference in survival compared with those patients receiving a weekly Kt/V = 4.2 (34) .
This study showed that there was an increase in UF values after three HVPD sessions, with stabilized values around 1.2 l after four HVPD sessions. For this study, different glucose concentrations were used according to Gabriel et al. (6, 23) , and these studies showed UF values around 2 L/session. However, a UF between 1 and 2 L is not enough for most AKI patients, who are mainly septic and with fluid overload. Concerning infectious complications, the rate of peritonitis was similar to the rates reported in the literature (12%-15%). Most of the patients had their catheter removed and dialysis method changed, because no success was obtained with the treatment. The main mechanical complication was early leakage (10%), which is in agreement with other studies (6, 9, 11, 29) .
In this series, both mortality rate and recovery of renal function were similar to the results found by other authors (6,9,31-35) .
There was no significant difference between the S and NS patients treated with HVPD in relation to metabolic control and delivered dialysis dose, which is consistent with the works by The Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network (36) and Bellomo et al. (37) in the trials ATN and Randomized Evaluation of Normal versus Augmented Level Replacement Therapy Study, respectively.
NS patients had clinical parameters and prognostic scores more severe than S patients, such as higher age, more sepsis, lower urine output, and higher ATN-ISS and Acute Physiology and Chronic Health disease Classification System 2. The two groups presented statistically significant differences in UF and NB. After three HVPD sessions, UF and NB were statistically higher and less negative in S than NS patients. The number of HVPD sessions and follow-up time were also higher in the S group. These results agree with previous studies reporting that low urine output, fluid overload, and sepsis were associated with worse prognosis of AKI patients (38) . Recent studies have shown that fluid overload is a risk factor of death in critical patients (38, 39) . In chronic dialysis patients treated with automated PD, the work by Brown et al. (40) showed that UF lower than 750 ml/d was associated with death.
Concerning NB, unfortunately, critically ill patients are hardly capable of maintaining positive balance, especially when the situation of stress is not resolved. Additionally, an even higher delivery of dietary proteins may not be sufficient to obtain neutral or positive NB in situations of marked catabolism (41) . In the literature, the association of this parameter with clinical prognosis in AKI patients on dialysis has been reported. Our findings were similar to the findings in the work by Scheinkestel et al. (41) , which had the observation that the NB was inversely associated with hospital and intensive care unit outcomes.
The limitation of this study was that the results were not presented according to intention to treat. Patients who changed the dialysis method (from HVPD to HD) were excluded to survival analysis.
The findings of our study suggest that careful prescription and accurate measurement of efficiency may contribute to providing adequate treatment for most AKI patients without contraindications for PD use, allowing adequate metabolic and fluid control. Age and sepsis were risk factors associated with death, whereas follow-up time, urine output, UF, and NB were protective factors against mortality.
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